|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Anxiety Disorders | |||||
| Depressive Disorders | |||||
| Eating Disorders | |||||
| Obsessive Compulsive Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Depression | |||||
| Depressive Disorder | |||||
| Disease | |||||
| Obsessive-Compulsive Disorder | |||||
| 3 | More general conditions related to this trial | ||||
| Behavioral Symptoms | |||||
| Mental Disorders | |||||
| Mood Disorders | |||||
| Pathologic Processes | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Norepinephrine | |||||
| Serotonin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Agonists | |||||
| Adrenergic alpha-Agonists | |||||
| Autonomic Agents | |||||
| Cardiovascular Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Serotonin Agents | |||||
| Sympathomimetics | |||||
| Therapeutic Uses | |||||
| Vasoconstrictor Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||